stockrowHims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.
- Revenue
- +38.3%
- EPS
- −294.7%
- Free cash flow
- +5.09%
- Total debt
- +40.8%
Quarter to June 2026, against a year earlier
Follow HIMS
Alert me
Hims & Hers Health, Inc. (HIMS) Revenue
Hims & Hers Health, Inc.'s revenue for fiscal 2025 was $2.3B, up 59.0% from $1.5B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.6B. Over the past ten years it has ranged from $82.6M (fiscal 2019) to $2.3B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 6 consecutive fiscal years. Hims & Hers Health, Inc. ranks 13th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.3B | 59.00% |
| FY2024 | $1.5B | 69.33% |
| FY2023 | $872.0M | 65.49% |
| FY2022 | $526.9M | 93.81% |
| FY2021 | $271.9M | 82.77% |
| FY2020 | $148.8M | 80.18% |
| FY2019 | $82.6M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $753.2M | 23.86% |
| Mar 2026 | $608.1M | (1.57%) |
| Dec 2025 | $617.8M | 3.15% |
| Sep 2025 | $599.0M | 9.94% |
| 22 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| HIMS Hims & Hers Health, Inc. | $2.6B |
| ALKS Alkermes plc compare | $1.8B |
| LNTH Lantheus Holdings, Inc. compare | $1.6B |
| SUPN Indivior Pharmaceuticals Inc. compare | $1.4B |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $946.0M |
| LQDA Liquidia Corporation compare | $450.9M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $87.4M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on HIMS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement